Neville Rodie & Shaw Inc Abb Vie Inc. Transaction History

Neville Rodie & Shaw Inc

$1.36 Billion
Q3 2024

A detailed history of Neville Rodie & Shaw Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Neville Rodie & Shaw Inc holds 100,915 shares of ABBV stock, worth $18 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares

100,915

Previous 95,743 5.4%

Holding current value

$18 Million

Previous $16.4 Million 21.36%

% of portfolio

1.47%

Previous 1.25%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 01, 2024	BUY	$163.84 - $199.33 $847,380 - $1.03 Million	5,172 Added 5.4%	100,915 $19.9 Million
Q2 2024 Jul 01, 2024	BUY	$154.79 - $180.76 $117,949 - $137,739	762 Added 0.8%	95,743 $16.4 Million
Q1 2024 Apr 09, 2024	SELL	$159.82 - $182.1 $205,848 - $234,544	-1,288 Reduced 1.34%	94,981 $17.3 Million
Q4 2023 Jan 02, 2024	SELL	$137.6 - $154.97 $227,177 - $255,855	-1,651 Reduced 1.69%	96,269 $14.9 Million
Q3 2023 Oct 10, 2023	SELL	$133.59 - $154.65 $267,180 - $309,300	-2,000 Reduced 2.0%	97,920 $14.6 Million
Q2 2023 Jul 06, 2023	SELL	$132.51 - $164.9 $2.89 Million - $3.6 Million	-21,820 Reduced 17.92%	99,920 $13.5 Million
Q1 2023 Apr 04, 2023	SELL	$144.61 - $166.54 $129,425 - $149,053	-895 Reduced 0.73%	121,740 $19.4 Million
Q4 2022 Jan 03, 2023	SELL	$138.31 - $165.87 $65,835 - $78,954	-476 Reduced 0.39%	122,635 $19.8 Million
Q3 2022 Oct 04, 2022	SELL	$134.21 - $153.93 $69,386 - $79,581	-517 Reduced 0.42%	123,111 $16.5 Million
Q2 2022 Jul 06, 2022	SELL	$137.62 - $174.96 $287,075 - $364,966	-2,086 Reduced 1.66%	123,628 $18.9 Million
Q1 2022 Apr 05, 2022	SELL	$131.98 - $163.75 $25,472 - $31,603	-193 Reduced 0.15%	125,714 $20.5 Million
Q4 2021 Jan 05, 2022	SELL	$107.43 - $135.93 $106,355 - $134,570	-990 Reduced 0.78%	125,907 $17 Million
Q3 2021 Oct 06, 2021	SELL	$106.4 - $120.78 $50,540 - $57,370	-475 Reduced 0.37%	126,897 $13.7 Million
Q2 2021 Jul 06, 2021	SELL	$105.21 - $117.21 $41,242 - $45,946	-392 Reduced 0.31%	127,372 $14.3 Million
Q1 2021 Apr 08, 2021	SELL	$102.3 - $112.62 $247,975 - $272,990	-2,424 Reduced 1.86%	127,764 $13.8 Million
Q4 2020 Mar 04, 2021	SELL	$80.49 - $108.67 $463,461 - $625,721	-5,758 Reduced 4.24%	130,188 $14 Million
Q3 2020 Oct 01, 2020	BUY	$85.91 - $100.83 $714,771 - $838,905	8,320 Added 6.52%	135,946 $11.9 Million
Q2 2020 Jul 15, 2020	BUY	$73.37 - $98.18 $2.22 Million - $2.98 Million	30,307 Added 31.14%	127,626 $12.5 Million
Q1 2020 Apr 01, 2020	BUY	$64.5 - $97.79 $746,587 - $1.13 Million	11,575 Added 13.5%	97,319 $7.42 Million
Q4 2019 Jan 08, 2020	SELL	$72.13 - $90.25 $5,409 - $6,768	-75 Reduced 0.09%	85,744 $7.59 Million
Q3 2019 Oct 02, 2019	SELL	$62.98 - $75.72 $151,152 - $181,728	-2,400 Reduced 2.72%	85,819 $6.5 Million
Q2 2019 Jul 01, 2019	SELL	$65.7 - $83.98 $705,223 - $901,441	-10,734 Reduced 10.85%	88,219 $6.42 Million
Q1 2019 Apr 08, 2019	SELL	$77.14 - $90.79 $864,430 - $1.02 Million	-11,206 Reduced 10.17%	98,953 $7.98 Million
Q4 2018 Jan 03, 2019	SELL	$77.85 - $96.01 $151,807 - $187,219	-1,950 Reduced 1.74%	110,159 $10.2 Million
Q3 2018 Oct 09, 2018	SELL	$88.91 - $98.84 $208,138 - $231,384	-2,341 Reduced 2.05%	112,109 $10.6 Million
Q2 2018 Jul 03, 2018	SELL	$89.78 - $106.23 $410,294 - $485,471	-4,570 Reduced 3.84%	114,450 $10.6 Million
Q1 2018 Apr 12, 2018	SELL	$92.01 - $123.21 $234,901 - $314,555	-2,553 Reduced 2.1%	119,020 $11.3 Million
Q4 2017 Jan 03, 2018	SELL	$89.56 - $98.21 $416,454 - $456,676	-4,650 Reduced 3.68%	121,573 $11.8 Million
Q3 2017 Oct 03, 2017	BUY	$69.85 - $89.22 $8.82 Million - $11.3 Million	126,223	126,223 $11.2 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $315B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neville Rodie & Shaw Inc, based on Form 13F filings with the SEC.

News

Stay updated on Neville Rodie & Shaw Inc with notifications on news.

Account

Neville Rodie & Shaw Inc Abb Vie Inc. Transaction History